Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.
What's in the News
- The Board of Directors of CareRx Corporation has authorized a buyback plan, announced on September 15, 2025. (Key Developments)
- CareRx Corporation has announced a share repurchase program that allows the company to repurchase up to 1,500,000 common shares, representing 2.5% of its issued share capital. The program will expire on September 16, 2026. (Key Developments)
- Between July 1, 2025 and September 6, 2025, CareRx repurchased 158,862 shares for CAD 0.42 million. This completed a total repurchase of 645,032 shares for CAD 1.6 million as part of a previously announced buyback. (Key Developments)
Valuation Changes
- Fair Value Estimate: Increased from CA$4.00 to CA$4.86, reflecting improved outlook.
- Discount Rate: Remained stable, moving only slightly from 6.55% to 6.55%.
- Revenue Growth: Risen modestly, estimated at 5.75% up from 5.44%.
- Net Profit Margin: Improved from 1.07% to 1.46%.
- Future P/E Ratio: Fell notably from 77.21x to 60.45x.
Have other thoughts on CareRx?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.